News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
594,787 Results
Type
Article (23779)
Company Profile (319)
Press Release (570684)
Multimedia
Podcasts (118)
Webinars (15)
Section
Business (196388)
Career Advice (441)
Deals (30282)
Drug Delivery (63)
Drug Development (75318)
Employer Resources (39)
FDA (13008)
Job Trends (10888)
News (291740)
Policy (22939)
Tag
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (3)
2027 Biotech Bay Elite (4)
2027 Biotech Bay Standard (5)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (5)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (1357)
Accelerated approval (51)
ADA (38)
Adcomms (29)
Allergies (155)
Alliances (41834)
ALS (223)
Alzheimer's disease (1534)
Antibody-drug conjugate (ADC) (571)
Approvals (13601)
Artificial intelligence (596)
ASCO (318)
Autoimmune disease (360)
Automation (36)
Bankruptcy (303)
Best Places to Work (8803)
BIO (66)
Biologics (2)
BIOSECURE Act (7)
Biosimilars (191)
BioSpace Insights (82)
Biotechnology (226)
Bladder cancer (199)
Brain cancer (66)
Breast cancer (780)
Cancer (6089)
Cardiovascular disease (453)
Career advice (379)
Career pathing (14)
CAR-T (342)
CDC (9)
Celiac Disease (1)
Cell therapy (922)
Cervical cancer (45)
Clinical research (67211)
Collaboration (2089)
Commercialization (6)
Company closure (3)
Compensation (1609)
Complete response letters (81)
COVID-19 (1522)
CRISPR (124)
C-suite (1159)
Cystic fibrosis (149)
Data (8300)
Denatured (26)
Depression (169)
Dermatology (99)
Diabetes (538)
Diagnostics (4902)
Digital health (46)
Diversity (6)
Diversity, equity & inclusion (12)
Drug discovery (363)
Drug pricing (69)
Drug shortages (5)
Duchenne muscular dystrophy (324)
Earnings (81394)
Editorial (39)
Employer branding (6)
Employer resources (37)
Events (104956)
Executive appointments (1000)
FDA (16666)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (25)
Frontotemporal dementia (35)
Funding (1680)
Gene editing (261)
Generative AI (45)
Gene therapy (727)
GLP-1 (757)
Government (1934)
Grass and pollen (4)
Guidances (344)
Healthcare (12272)
Hematology (173)
HIV (80)
Huntington's disease (62)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (123)
Immunology and inflammation (316)
Immuno-oncology (109)
Indications (220)
Infectious disease (1799)
Inflammatory bowel disease (221)
Inflation Reduction Act (12)
Influenza (95)
Intellectual property (314)
Interviews (58)
IPO (14558)
IRA (16)
Job creations (2476)
Job search strategy (343)
JPM (44)
Kidney cancer (25)
Labor market (36)
Layoffs (358)
Leadership (15)
Legal (5709)
Licensing (12)
Liver cancer (82)
Longevity (31)
Lung cancer (856)
Lymphoma (439)
Machine learning (47)
Management (9)
Manufacturing (849)
Marketing (12)
MASH (190)
Medical affairs (1)
Medical device (9925)
Medtech (10089)
Mergers & acquisitions (16949)
Metabolic disorders (1302)
mRNA (196)
Multiple sclerosis (187)
NASH (15)
Neurodegenerative disease (449)
Neuropsychiatric disorders (111)
Neuroscience (3123)
Neurotech (1)
NextGen: Class of 2026 (4178)
Non-profit (1571)
Now hiring (42)
Obesity (543)
Opinion (164)
Ovarian cancer (242)
Pain (245)
Pancreatic cancer (334)
Parkinson's disease (384)
Partnered (21)
Patents (613)
Patient recruitment (802)
Peanut (57)
People (49887)
Pharmaceutical (50)
Pharmacy benefit managers (13)
Phase 1 (21725)
Phase 2 (30046)
Phase 3 (21226)
Pipeline (10011)
Policy (127)
Postmarket research (2075)
Preclinical (9213)
Press Release (52)
Prostate cancer (318)
Psychedelics (75)
Radiopharmaceuticals (347)
Rare diseases (1159)
Real estate (3802)
Recruiting (14)
Regulatory (20303)
Reports (33)
Research institute (1432)
Resumes & cover letters (59)
Rett syndrome (48)
RNA editing (31)
RSV (60)
Schizophrenia (178)
Series A (312)
Series B (222)
Service/supplier (5)
Sickle cell disease (119)
Special edition (21)
Spinal muscular atrophy (149)
Sponsored (25)
Startups (3147)
State (1)
Stomach cancer (17)
Supply chain (77)
Tariffs (19)
The Weekly (90)
Vaccines (596)
Venture capital (108)
Weight loss (289)
Women's health (106)
Worklife (3)
Date
Today (81)
Last 7 days (430)
Last 30 days (2231)
Last 365 days (26676)
2026 (17243)
2025 (26549)
2024 (30761)
2023 (34722)
2022 (44203)
2021 (46647)
2020 (41761)
2019 (30664)
2018 (23090)
2017 (25032)
2016 (23403)
2015 (29532)
2014 (25368)
2013 (21042)
2012 (22806)
2011 (23076)
2010 (22781)
Location
Africa (347)
Alabama (92)
Alaska (3)
Arizona (343)
Arkansas (14)
Asia (30159)
Australia (4622)
California (13977)
Canada (3768)
China (1419)
Colorado (565)
Connecticut (555)
Delaware (408)
Europe (57781)
Florida (2048)
Georgia (425)
Hawaii (4)
Idaho (47)
Illinois (938)
India (91)
Indiana (475)
Iowa (18)
Japan (554)
Kansas (117)
Kentucky (41)
Louisiana (49)
Maine (37)
Maryland (1506)
Massachusetts (10042)
Michigan (323)
Minnesota (636)
Mississippi (5)
Missouri (101)
Montana (32)
Nebraska (14)
Nevada (132)
New Hampshire (75)
New Jersey (3418)
New Mexico (19)
New York (3408)
North Carolina (1685)
North Dakota (9)
Northern California (7187)
Ohio (346)
Oklahoma (15)
Oregon (35)
Pennsylvania (2714)
Puerto Rico (24)
Rhode Island (37)
South America (545)
South Carolina (77)
South Dakota (1)
Southern California (5535)
Tennessee (154)
Texas (2204)
United States (47362)
Utah (405)
Vermont (1)
Virginia (257)
Washington D.C. (51)
Washington State (1109)
West Virginia (2)
Wisconsin (112)
Wyoming (1)
594,787 Results for "inhibitor therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
August 18, 2026
·
4 min read
Press Releases
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS
July 29, 2026
·
11 min read
Cardiovascular disease
Novo’s IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%
Novo Nordisk’s IL-6 inhibitor ziltivekimab failed to reduce the risk of cardiovascular events in the late-stage trial, dashing hopes for an edge in the hyper-competitive cardiometabolic space.
July 31, 2026
·
2 min read
·
Michael Gibney
Press Releases
Arisan Therapeutics Selected for NIAID Contract Award to Develop a Therapeutic Small Molecule Viral Entry Inhibitor as a Medical Countermeasure for Filovirus Infection
August 13, 2026
·
5 min read
Press Releases
CHARM Therapeutics announces formation of Clinical Advisory Board to support advancement of CHM-029, its next-generation menin inhibitor
August 18, 2026
·
6 min read
Approvals
Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor
Merck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.
July 16, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
Expedition Therapeutics Announces Oversubscribed $115 Million Series B Financing to Advance Next-Generation DPP1 Inhibitor for COPD
August 5, 2026
·
4 min read
Press Releases
BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC
August 18, 2026
·
6 min read
Press Releases
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
August 3, 2026
·
7 min read
Press Releases
HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026
June 4, 2026
·
3 min read
1 of 59,479
Next
